Mail Us
Global.CustomerService@glenmarkpharma.com
Call Us
1800 266 6255
Global.CustomerService@glenmarkpharma.com
1800 266 6255
AACE Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm provides concise visual guidance in the form of algorithms to assist with clinical decision-making for the management of persons with type 2 diabetes mellitus and related comorbidities and complications. It incorporates newer therapies and management approaches that build on previous versions of the algorithm but also aligns with the 2022 update of the AACE evidence-based clinical practice guideline “Developing a Diabetes Mellitus Comprehensive Care Plan.”
The current ESC 2023 Guidelines on cardiovascular disease and diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes.
This version of the Guidelines gives recommendations on CV risk stratification as well as on screening, diagnosis, and treatment of CVD in patients with diabetes. Based on evidence from large CVOTs, the current Guidelines provide clear recommendations on how to reduce cardiovascular risk in patients with diabetes and how to treat patients with diabetes and clinical manifestations of cardio-renal disease such as atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, and chronic kidney disease.
The current ESC 2023 Guidelines on cardiovascular disease and diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes.
This version of the Guidelines gives recommendations on CV risk stratification as well as on screening, diagnosis, and treatment of CVD in patients with diabetes. Based on evidence from large CVOTs, the current Guidelines provide clear recommendations on how to reduce cardiovascular risk in patients with diabetes and how to treat patients with diabetes and clinical manifestations of cardio-renal disease such as atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, and chronic kidney disease.
This guideline include putting more emphasis on the health care system, social determinants of health, and physical exercise habits, including sleep. The holistic approach to managing diabetes places more of an emphasis on weight control. Broader recommendations for cardiorenal protection in diabetics at high risk of cardiorenal disease are informed by the findings of cardiovascular and kidney outcomes trials involving glucagon-like peptide 1 receptor agonists and other drugs, including subgroup analyses. A synopsis of the consensus proposals is followed by helpful implementation advice.